Regeneron Pharmaceuticals, Inc.’s Eylea HD (aflibercept) is off to a strong start as the wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) drug saw sales of $123m in its first full quarter on the market, which the drug maker expects to grow as reimbursement becomes more straightforward. Meanwhile, Regeneron anticipates its immuno-oncology drug Libtayo will reach blockbuster sales this year, with multiple key catalysts to come for its growing oncology segment.
Regeneron Sees Further Growth For Eylea HD As Reimbursement Path Gets Smoother
The drug maker reported $123m in sales for the higher-dose version of Eylea in the first full quarter of sales since its approval last August.
More from Earnings
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
More from Business
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.